| Identification | Back Directory | [Name]
Spiro[1,2-benzisoxazole-7(4H),4′(5′H)-benzo[b]thiophene]-3′-carbonitrile, 2′-amino-5,6,6′,7′-tetrahydro-3-[2-[(2S)-2-methyl-1-piperazinyl]-4-pyrimidinyl]-, (4′S)- | [CAS]
2937344-16-4 | [Synonyms]
Spiro[1,2-benzisoxazole-7(4H),4′(5′H)-benzo[b]thiophene]-3′-carbonitrile, 2′-amino-5,6,6′,7′-tetrahydro-3-[2-[(2S)-2-methyl-1-piperazinyl]-4-pyrimidinyl]-, (4′S)- | [Molecular Formula]
C24H27N7OS | [MOL File]
2937344-16-4.mol | [Molecular Weight]
461.58 |
| Chemical Properties | Back Directory | [Boiling point ]
774.2±70.0 °C(Predicted) | [density ]
1.41±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted) | [form ]
Solid | [pka]
8.62±0.40(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
BI-2493 is a structural analog of BI-2865 and a highly selective pan-KRAS inhibitor. This compound can attenuate tumor growth and can also be used for cancer disease research. | [in vivo]
BI-2493 (90 mg/kg, p.o., twice daily for 21 days) exhibits tumor-suppressive activity in LS513/GP2d/HPAC/SW620/MIAPACA2-derived xenograft NMRI mice models[1]. | Animal Model: | LS513/GP2d/HPAC/SW620/MIAPACA2-derived xenograft NMRI mice models | | Dosage: | 90 mg/kg | | Administration: | Oral gavage (p.o.), twice daily for 21 days | | Result: | Reduced tumor growth in mice carrying KRAS G12C, G12D, G12V, and A146V mutation models, without causing significant toxicity to the mice. |
| [IC 50]
K-Ras WT |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|